B
Bullisch
Bullisch · 25%ANAB
$53.20
Szenariopreis
$48.710
-0.019 (-0.04%)Zum Schluss
Loading chart…
- Hoch
- 49.620
- Eröffnung
- 48.970
- Volumengewichteter Durchschnittskurs
- 48.77
- Volumen
- 417.18K
- Marktkap.
- 677.50M
- Tief
- 47.980
- Umsatz
- 20.35M
- EV/EBITDA, TTM
- 16.81
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
KI-Analyse of AnaptysBio, Inc. (ANAB)
KaufenAnaptysBio Inc appears to be a good buy right now, trading at $48.73 with a forward P/E of 21.01, which is reasonable compared to its growth potential. The recent FDA approval of Jemperli for advanced rectal cancer could significantly enhance revenue streams, and the stock has shown a 34.69% increase over the past year. However, the company faces risks with a high debt-to-equity ratio of 2423.17%, indicating potential financial instability.
Analystenbewertungen (8)
+52.19% Aufwärtspotenzial
Kaufen
8 Kaufen
0 Halten
0 Verkaufen
Aktuell: 48.71
Tief
50.00
Durchschnitt
74.13
Hoch
140.00
JPMorgan
Übergewichten
$60
2026-09-30
JPMorgan
2026-09-30
Kursziel
$60
Übergewichten
TD Cowen
Kaufen
$70
2026-08-25
TD Cowen
2026-08-25
Kursziel
$70
Kaufen
Leerink
Überdurchschnittlich
$90
2026-05-15
Leerink
2026-05-15
Kursziel
$90
Überdurchschnittlich
UBS
Kaufen
$76
2026-05-13
UBS
2026-05-13
Kursziel
$76
Kaufen
Barclays
Übergewichten
$75
2026-05-13
Barclays
2026-05-13
Kursziel
$75
Übergewichten
Bewertungskennzahlen
Das aktuelle erwartete KGV von AnaptysBio, Inc. (ANAB) beträgt 21.01, verglichen mit dem 5-Jahres-Durchschnitt von -3.35.
Alphio-AI-Kursszenarien für ANAB
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die ANAB halten
Event-Zeitleiste
News
8.510-19NewsfilterFDA Approves Jemperli for Advanced Rectal Cancer Treatment
9.509-22NASDAQ.COMAnaptysBio Reports Significant Q2 Profit Growth Driven by Tax Benefits
9.505-12seekingalphaAnaptysBio Q1 Earnings Report Analysis
- 5.005-11Newsfilter
AnaptysBio Strengthens Leadership Team and Board
9.004-28PRnewswireVanda Pharmaceuticals Publishes Imsidolimab Research Findings
ANAB FAQ – beantwortet von Alphio AI
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
AnaptysBio Inc appears to be a good buy right now, trading at $48.73 with a forward P/E of 21.01, which is reasonable compared to its growth potential. The recent FDA approval of Jemperli for advanced rectal cancer could significantly enhance revenue streams, and the stock has shown a 34.69% increase over the past year. However, the company faces risks with a high debt-to-equity ratio of 2423.17%, indicating potential financial instability.
8 analysts cover ANAB: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 74.13.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.